How effective is targeted therapy for lung cancer? The effect is good

The effect of targeted therapy for lung cancer is still good. After all, there are many drugs of this type, and patients have a wide range of choices. For lung adenocarcinoma, if the EGFR gene mutation occurs, Iressa can be chosen; if the ALK gene mutation occurs, crizotinib can be chosen; if the patient does not have a gene mutation, anlotinib can be chosen.

In real life, due to various reasons, it has caused great harm to the patient's health, induced the occurrence of lung cancer, and is also very detrimental to improving the quality of life. It is necessary to treat it as soon as possible while the condition is not serious. So, what is the effect of targeted treatment for lung cancer? Let's find out below!
The effect of targeted therapy for lung cancer often varies from person to person. However, this treatment method, in general, has a good therapeutic effect compared to traditional chemotherapy and radiotherapy. As for the specific therapeutic effect of targeted therapy for lung cancer, it is necessary to observe the patient during the treatment process to know the therapeutic effect. In addition, it should be noted that targeted drugs can also be used in combination with radiotherapy and chemotherapy during the treatment process, or they can be used alone.
Lung cancer is a malignant tumor that occurs in the respiratory system and is located in the patient's chest. Generally speaking, the treatment of lung cancer often requires surgical treatment as a comprehensive treatment plan, and targeted treatment of lung cancer is only one part of this comprehensive treatment plan.
Generally speaking, the application of targeted treatment for lung cancer is still quite widespread at present, and the overall treatment effect is also quite good. The reason is that there are often many types of targeted drugs that can be selected for the occurrence of lung cancer, so it provides patients with a lot of choices.
If the patient suffers from lung adenocarcinoma and the EGFR gene has mutated, then Tarceva and Iressa, in addition to other lung cancer targeted drugs such as Conmana, can be used for treatment; if the ALK gene mutation occurs, then crizotinib and other targeted drugs can be used for treatment; if the patient does not have a gene mutation, such as lung adenocarcinoma and non-small cell lung adenocarcinoma, they can also be treated with targeted therapy drugs such as anlotinib; for cancers such as squamous cell lung carcinoma, there are relatively few targeted drugs to choose from, but anlotinib can be considered.